FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892041353> ?p ?o ?g. }

• W2892041353 abstract "e19011 Background: Pembrolizumab has shown a high response in patients classic Hodgkin lymphoma (cHL) patients who have experienced disease progression after brentuximab vedotin in KEYNOTE (KN)-087 and the results have been presented. This study aimed to evaluate the health-related quality of life (HRQoL) of the trial patients in KN087. Methods: KN-087 is an ongoing single-arm multi-center, non-randomized Phase II trial evaluating pembrolizumab 200mg Q3W IV in patients with relapsed or refractory cHL. In KN-087, HRQoL data were collected at baseline and every drug administration over the 18 months of follow-up. HRQoL was assessed using both the EQ-5D and EORTC QLQ-C30 instruments. The generic health statuses assessed from both instrument were converted to population-based utility values using published algorithms. More specifically, US-based scoring was applied to US patients, UK-based scoring for UK patients and EU-based scoring for all other patients. HRQoL was reported by status of respond and disease progression. Response was defined based upon IWG criteria. Furthermore, stratified analyses were conducted to examine the health disabilities of the patients who experienced grade 3+ adverse events (AEs), and by ECOG performance and the number of prior therapies. Results: Among 210 trial patients, HRQoL data were collected for 205 patients at baseline and the mean health utility score was 0.759 (95% CI 0.730-0.788). Mean health utility score among responders and non-responders was 0.826 (95% CI 0.811-0.842) and 0.760 (95% CI 0.718-0.801), respectively. The difference is considered clinically significant. Mean utility decreased from 0.820 (95% CI 0.807-0.833) for time spent prior to progression to 0.806 (95% CI 0.780-0.832) post disease progression. Progression-free patients who experienced grade 3+ AEs (N=17) had a mean health utility of 0.736 (95% CI 0.662-0.811), compared with 0.825 (95% CI 0.811-0.838) among those did not. Conclusions: The results showed a substantial HRQoL impact of R/R cHL. Treatment response was associated with significant clinically meaningful improvement in HRQoL. The utility estimates from the study are important for economic evaluations of treatments in R/R cHL patients. Clinical trial information: NCT02453594." @default.
• W2892041353 created "2018-09-27" @default.
• W2892041353 creator A5026750081 @default.
• W2892041353 creator A5051298107 @default.
• W2892041353 creator A5064984516 @default.
• W2892041353 date "2017-05-20" @default.
• W2892041353 modified "2023-10-06" @default.
• W2892041353 title "A trial-based EuroQol EQ-5D health utility analysis in patients with classical Hodgkin lymphoma." @default.
• W2892041353 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.e19011" @default.
• W2892041353 hasPublicationYear "2017" @default.
• W2892041353 type Work @default.
• W2892041353 sameAs 2892041353 @default.
• W2892041353 citedByCount "1" @default.
• W2892041353 countsByYear W28920413532018 @default.
• W2892041353 countsByYear W28920413532022 @default.
• W2892041353 crossrefType "journal-article" @default.
• W2892041353 hasAuthorship W2892041353A5026750081 @default.
• W2892041353 hasAuthorship W2892041353A5051298107 @default.
• W2892041353 hasAuthorship W2892041353A5064984516 @default.
• W2892041353 hasConcept C126322002 @default.
• W2892041353 hasConcept C143998085 @default.
• W2892041353 hasConcept C2778464720 @default.
• W2892041353 hasConcept C2779134260 @default.
• W2892041353 hasConcept C2779338263 @default.
• W2892041353 hasConcept C2910914307 @default.
• W2892041353 hasConcept C2992779791 @default.
• W2892041353 hasConcept C3019006561 @default.
• W2892041353 hasConcept C535046627 @default.
• W2892041353 hasConcept C71924100 @default.
• W2892041353 hasConceptScore W2892041353C126322002 @default.
• W2892041353 hasConceptScore W2892041353C143998085 @default.
• W2892041353 hasConceptScore W2892041353C2778464720 @default.
• W2892041353 hasConceptScore W2892041353C2779134260 @default.
• W2892041353 hasConceptScore W2892041353C2779338263 @default.
• W2892041353 hasConceptScore W2892041353C2910914307 @default.
• W2892041353 hasConceptScore W2892041353C2992779791 @default.
• W2892041353 hasConceptScore W2892041353C3019006561 @default.
• W2892041353 hasConceptScore W2892041353C535046627 @default.
• W2892041353 hasConceptScore W2892041353C71924100 @default.
• W2892041353 hasLocation W28920413531 @default.
• W2892041353 hasOpenAccess W2892041353 @default.
• W2892041353 hasPrimaryLocation W28920413531 @default.
• W2892041353 hasRelatedWork W2016561240 @default.
• W2892041353 hasRelatedWork W2397619099 @default.
• W2892041353 hasRelatedWork W2591641966 @default.
• W2892041353 hasRelatedWork W2618992884 @default.
• W2892041353 hasRelatedWork W2623606780 @default.
• W2892041353 hasRelatedWork W2742751730 @default.
• W2892041353 hasRelatedWork W2804430290 @default.
• W2892041353 hasRelatedWork W2890118645 @default.
• W2892041353 hasRelatedWork W2896901630 @default.
• W2892041353 hasRelatedWork W2942212268 @default.
• W2892041353 hasRelatedWork W2949614109 @default.
• W2892041353 hasRelatedWork W2949891040 @default.
• W2892041353 hasRelatedWork W2987280972 @default.
• W2892041353 hasRelatedWork W3008503788 @default.
• W2892041353 hasRelatedWork W3029133298 @default.
• W2892041353 hasRelatedWork W3088397291 @default.
• W2892041353 hasRelatedWork W3113116520 @default.
• W2892041353 hasRelatedWork W3173354810 @default.
• W2892041353 hasRelatedWork W3177413580 @default.
• W2892041353 hasRelatedWork W3187226803 @default.
• W2892041353 isParatext "false" @default.
• W2892041353 isRetracted "false" @default.
• W2892041353 magId "2892041353" @default.
• W2892041353 workType "article" @default.